MedTrace Logo

Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy

NCT00355082 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2017-01-02

Study results available
· View outcomes & findings →

Summary

This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.

Conditions

  • Epilepsy, Partial

Interventions

DRUG

lamotrigine, 300 mg/day

300 mg/day

DRUG

lamotrigine, 250 mg/day

250 mg/day

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States
  • Argentina
  • Chile
  • Costa Rica
  • Puerto Rico
  • Russia
  • South Korea
  • Ukraine

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00355082 on ClinicalTrials.gov